Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerBilling CodesProprietary Laboratory AnalysesCPT cpt-0268u-versiti-ahus-genetic-evaluation-ngs-15-genes
    Ask Trek AI about this page

    CPT 0268U: Versiti aHUS Genetic Evaluation, 15-Gene NGS Panel

    CPT code 0268U is a Proprietary Laboratory Analyses (PLA) code for the Versiti™ aHUS Genetic Evaluation performed by Versiti™ Diagnostic Laboratories; the test uses next-generation sequencing (NGS) of 15 genes associated with atypical hemolytic uremic syndrome (aHUS) and is intended to aid in diagnosis, inform therapeutic decision-making, or assess familial risk. Service type: molecular genetic testing / NGS panel. Typical site of service: reference diagnostic laboratory or specialty clinical laboratory, with specimens such as blood, buccal swab, or amniotic fluid.

    For related coverage guidance, see recent payer policy updates: Minimal Residual Disease (MRD) Testing for Cancer, Biomarker Testing Mandate, Prenatal (Fetal) Diagnostic Testing.

    Customize your policy alerts

    Sign up for cpt 0268U policy alerts

    Get alerted when payer policies referencing 0268U are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Table of contents

    Progress1 / 7

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical & Coding Specifications

    Clinical Context

    A 28-year-old patient presents with recurrent episodes of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury consistent with a suspected atypical hemolytic uremic syndrome (aHUS). The nephrologist orders genetic testing to identify pathogenic variants in complement pathway genes that may influence diagnosis, prognosis, family risk counseling, and targeted therapy selection (for example, complement inhibitors). A blood draw is obtained during an outpatient visit; buccal swab or amniotic fluid may be used when blood is not available or for prenatal/family studies. The specimen is sent to Versiti™ Diagnostic Laboratories for the proprietary Versiti™ aHUS Genetic Evaluation. The laboratory performs next-generation sequencing (NGS) of 15 aHUS-relevant genes and returns a report describing pathogenic, likely pathogenic, and variants of uncertain significance, with recommendations for genetic counseling and familial testing as appropriate. Results are reviewed by the ordering clinician to guide therapy decisions (such as initiation or continuation of complement inhibition), clarify etiology, and inform cascade testing of relatives. Typical site of service is an outpatient clinic, hospital outpatient laboratory, or reference laboratory; specimen collection may occur in clinic, inpatient ward, or ambulatory phlebotomy site.

    Related CPT Codes

    CPT CodeDescriptionRelationship to This Procedure
    0268UVersiti™ aHUS Genetic Evaluation — NGS analysis of 15 genes relevant to aHUS (Proprietary Laboratory Analyses)Primary code for the proprietary laboratory test performed by Versiti™ Diagnostic Laboratories on blood, buccal swab, or amniotic fluid to assess genetic causes of aHUS.
    81211BRCA1 gene analysis; full gene sequence analysisExample of a hereditary disease full-gene NGS sequencing CPT used as a workflow analog for laboratory and billing processes when pedigree-based testing is performed.
    81217HFE (hemochromatosis) gene analysis; common variants panelRepresents targeted genetic testing panels often performed alongside genetic counseling and family risk assessment workflows.
    81479Unlisted molecular pathology procedureUsed when a specific proprietary test lacks an applicable analyte-specific CPT and payer requires an unlisted code for additional billing scenarios.
    36415Collection of venous blood by venipunctureSpecimen collection code commonly performed before sending sample to the reference lab for 0268U testing.

    Note: Only 0268U is the PLA code for the Versiti™ aHUS Genetic Evaluation. Other listed CPT codes are commonly associated procedures (specimen collection, alternative genetic tests, or unlisted molecular reporting) that may appear in the clinical workflow.

    Related Modifiers

    6 rows

    ModifierDescriptionWhen to Use
    26Modifier 26 (Professional Component) identifies and bills only the professional portion of a split service — the physician’s interpretation, report, and medical judgment — when the technical…- Use CPT Modifier -26 when you are billing only the professional component (PC) of a split‑bill eligible service—i.e., you performed the physician interpretation, medical judgment and prepared a…
    52Modifier ‑52 (Reduced Services) indicates that a service or procedure was partially reduced or omitted at the provider’s discretion, allowing reporting of the basic procedure number with a qualifier…- Use modifier -52 when a physician or qualified health professional electively reduces or omits part of a procedure or service (for example, performing fewer required views or omitting a portion of…
    53Modifier 53 (Discontinued Procedure) signals that a surgical or diagnostic service was begun by the physician but terminated because of extenuating circumstances that threatened the patient’s…- Use modifier -53 when a physician/qualified healthcare professional has started a surgical or diagnostic procedure (e.g., anesthesia administered, incision or scope insertion) and then discontinues…
    62Modifier 62 indicates that two surgeons function as co‑surgeons, each performing distinct parts of the same primary surgical procedure. It is appended to the primary procedure code (and any…- Use modifier -62 when two surgeons act as co‑surgeons (both primary surgeons) on a single definitive primary procedure, each performing distinct parts of the same surgical procedure (append -62 to…
    78CPT modifier -78 indicates an unplanned, related return to the operating or procedure room by the same provider during the global postoperative period. It is appended when treatment for a…- Use modifier -78 when an unplanned, related complication during the original procedure’s global postoperative period requires the patient to return to a formal operating or procedure room and the…
    80CPT® Modifier 80 (Assistant Surgeon) is appended to a surgical CPT code when a physician (MD or DO) provides full, continuous assistance throughout the operative procedure. It is intended only for…- Use CPT Modifier -80 when a physician (MD or DO) serves as an assistant surgeon and provides full, continuous assistance throughout the entire operative procedure; append -80 to the surgical CPT…

    Related Provider Taxonomies

    8 rows

    Taxonomy Code
    2080P0206X
    207L00000X
    207K00000X
    363L00000X
    251B00000X
    207T00000X
    207YP0228X
    163WP2201X

    Related ICD-10-CM Codes

    23 rows

    ICD-10-CM CodeDescription
    D59.8Other acquired hemolytic anemias
    D61.9Aplastic anemia, unspecified
    D63.8Anemia in other chronic diseases classified elsewhere
    D68.9Coagulation defect, unspecified
    E83.52Hypercalcemia
    I10Essential (primary) hypertension
    N17.9Acute kidney failure, unspecified
    N18.4Chronic kidney disease, stage 4 (severe)
    N18.9Chronic kidney disease, unspecified
    N25.9Disorder resulting from impaired renal tubular function, unspecified

    Showing 1–10 of 23

    Related Payer Policy Updates

    Specialty: Genetic & Molecular Testing1 / 3

    10 rows

    PolicyPayerEffective Date
    Minimal Residual Disease (MRD) Testing for Cancerregence2027-01-01
    Biomarker Testing MandateBlue Cross Blue Shield - Rhode Island2027-01-01
    Prenatal (Fetal) Diagnostic TestingBlue Cross Blue Shield - Rhode Island2027-01-01
    Oral Cancer Screening and TestingOscar Health2027-01-01
    RTM Testing for Alpha-1 Antitrypsin DeficiencyOscar Health2027-01-01
    Cytochrome P450 Genotype-Guided Treatment Strategy Corporate Medical Policybcbsvermont2027-01-01
    Cytochrome P450 Genotypingblue cross blue shield - tennessee2026-12-31
    Polygenic Risk ScoreBlue Cross Blue Shield - Rhode Island2026-12-01
    Gene Expression Profiling for Cutaneous MelanomaBlue Cross Blue Shield - Rhode Island2026-12-01
    Chromosomal Microarray Testing for the Evaluation of Pregnancy Lossblue_shield_of_california2026-11-01

    Related Codes

    CPT-0001U-PRECISETYPE-HEA-MULTIPLEX-RBC-ANTIGEN-GENOTYPING

    CPT 0001U: PreciseType HEA Erythrocyte Antigen Genotyping

    CPT-0002U-POLYPDX-URINE-METABOLOMIC-ASSAY-ADENOMATOUS-POLYP-RISK

    CPT 0002U: PolypDX™ Urine Metabolomic Risk Assay

    CPT-0003U-OVAR-A-NEXT-GENERATION-OVARIAN-CANCER-RISK-ASSAY

    CPT 0003U: Overa (MIA2G) Ovarian Cancer Risk Assay

    CPT-0005U-PROSTATE-EXOSOMEDX-INTELLISCORE-GENE-EXPRESSION-URINE-TEST

    CPT 0005U: ExosomeDx Prostate (IntelliScore) urine gene expression test

    CPT-0007U-TOXPROTECT-URINE-DRUG-SCREEN-WITH-DNA-AUTHENTICATION

    CPT 0007U: ToxProtect Urine Drug Screen With DNA Authentication

    CPT-0008U-H-PYLORI-ANTIBIOTIC-RESISTANCE-SEQUENCING-PANEL

    CPT 0008U: H. pylori Antibiotic Resistance Gene Panel

    CPT-0009U-DEPARRAY-HER2-FISH-TUMOR-CELL-ISOLATION

    CPT 0009U: DEPArray HER2 Tumor‑Cell Isolation with FISH Analysis

    CPT-0010U-BACTERIAL-TYPING-WHOLE-GENOME-SEQUENCING-MAYO-CLINIC

    CPT 0010U: Bacterial Typing by Whole Genome Sequencing, Mayo Clinic

    CPT-0011U-CORDANT-CORE-ALGORITHMIC-ORAL-FLUID-DRUG-TEST

    CPT 0011U: Oral Fluid Drug Test with Algorithmic Steady‑State Comparison

    CPT-0016U-BCR-ABL1-MAJOR-MINOR-FUSION-TRANSCRIPT-TESTING

    CPT 0016U: BCR–ABL1 Major and Minor Breakpoint Fusion Transcripts

    Showing 1–10 of 536

    • More pages

    Frequently Asked Questions

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.